Screening
Table 1: Steps taken to overcome barriers to adopting HCS STEPS TAKEN
Improved data management and storage, IT infrastructure Purchased mature, proven, user-friendly equipment Improved ways to analyse data Improved speed of microscopes Automated process
Developing better dyes, kits
Considering laser-based instruments to improve throughput Expand instrumentations at high- and low-end
Miniaturised to 1536-well to improve speed to read a plate Pooling compounds to increase throughput Relying on external partners No improvements
© HighTech Business Decisions
NUMBER OF MENTIONS 10
8 6 3 2 2 1 1 1 1 1 3
“We utilise HCS only in secondary screening after primary screening, but as technology improves, costs decrease, and throughput increases, we anticipate moving HCS more to a primary screen- ing mode.”
Pharma/Biotech HTS Lab
“We use HCS in early screening programmes, lead discovery, or hit identification, as just one technol- ogy, in addition to other technologies. We antici- pate we will expand the amount of HCS in future. Clearly, if we run more phenotypic screens, we will need to run more HCS.”
Pharma/Biotech HTS Lab Conclusions
The majority of HTS laboratories have adopted HCS technologies into their laboratory operations. HCS is primarily being used in secondary screening operations, but there continues to be a trend toward its use in primary screening. Over the past five years, both HTS laboratories and their suppliers have worked to reduce these barriers to adoption. Yet, for many HTS Directors, there continues to be signifi- cant barriers for its continued adoption. Those bar- riers include costs, the current state of analytical software and data management, throughputs and the quality of antibodies and labels. Despite these barriers, HCS will continue to grow as the number of HTS laboratories continue to adopt HCS tech- nologies and expand its use.
DDW
William Downey is President and Dr Jennifer Hartigan is the senior scientific at HighTech Business Decisions, a consulting firm specialising in cus- tomised market analysis, industry reports and cus-
Drug Discovery World Spring 2013 57
tomer loyalty studies for suppliers serving the phar- maceutical and biotechnology industries. The com- pany recently published the report High Content Screening 2013: Expanded Use and Improved Technologies.
www.hightechdecisions.com.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80